AWARE: Management of ADHD in Autism Spectrum Disorder
Comparative Effectiveness of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder
Daniel Coury
500 participants
Oct 1, 2023
INTERVENTIONAL
Conditions
Summary
This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.
Eligibility
Inclusion Criteria10
- Participant and/or legal caregiver must be willing and able to give informed consent/assent for participation in this study.
- Participant and/or legal caregiver must be willing and able (in the Investigator's opinion) to comply with all study requirements.
- Participant must be between 4 and 17 years of age (inclusive) at time of enrollment.
- Participant must have a confirmed diagnosis of ASD based on supportive evidence (e.g. referring physician's report, medical records, such as ADOS or CARS, etc.).
- Participant must have the ability to consistently take medication (via pill, liquid or mixed with food/liquid).
- Participant must have a confirmed diagnosis of ADHD (based upon DSM-5 criteria and supportive evidence).
- Participant must have a consistent reporter (e.g., parent) who spends regular time with the child.
- Participant can be on other psychotropic medications (selective serotonin reuptake inhibitor (SSRI), atypical antipsychotic, anticonvulsant) if dose has been stable for > 4 weeks prior to consent with no plans for a dose change during the study.
- It has been at least 7 days since the participant last took an ADHD medication and the presiding clinician believes this to be a sufficient amount of time.
- Caregiver must be sufficiently fluent in English or Spanish to be able to complete questionnaires relevant to this study.
Exclusion Criteria3
- Participant has taken ADHD medication within the past 7 days.
- Participant is not stable on other medications (< 4 weeks).
- Any other risk factor that might prevent patient from safely taking the study medications.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)
If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue. Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05916339